Leica Biosystems, part of Danaher, agreed to acquire Statlab Medical Products to expand its diagnostics and anatomical pathology portfolio with additional consumables and instruments. Financial terms were not disclosed, but RBC Capital Markets analysts estimated the deal could exceed $1 billion. The move aligns with Danaher’s strategy to deepen presence in pathology workflows, where integrated offerings—reagents, instruments, and consumables—often support recurring revenue and broaden installed base. For the sector, the deal is another example of consolidation in med-tech tools as larger platforms compete to control more of the end-to-end pathology and molecular testing stack.